These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 30483992)
1. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Gao M; Zhu L; Chang J; Cao T; Song L; Wen C; Chen Y; Zhuo Y; Chen F Clin Drug Investig; 2023 Jan; 43(1):1-11. PubMed ID: 36462105 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ; Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181 [TBL] [Abstract][Full Text] [Related]
4. Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Huang SL; Shen YL; Peng WY; Ye K; Zheng H Acta Neurol Belg; 2024 Jun; 124(3):895-904. PubMed ID: 38347315 [TBL] [Abstract][Full Text] [Related]
5. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). Shefner J; Heiman-Patterson T; Pioro EP; Wiedau-Pazos M; Liu S; Zhang J; Agnese W; Apple S Muscle Nerve; 2020 Feb; 61(2):218-221. PubMed ID: 31621933 [TBL] [Abstract][Full Text] [Related]
6. Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta-analysis of randomized controlled trials. Chen C; Li M; Lin L; Chen S; Chen Y; Hong L J Clin Pharm Ther; 2021 Aug; 46(4):907-917. PubMed ID: 33638896 [TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC; JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. Fortuna A; Gizzi M; Bello L; Martinelli I; Bertolin C; Pegoraro E; Corbetta M; Sorarù G; J Neurol Sci; 2019 Sep; 404():47-51. PubMed ID: 31325668 [TBL] [Abstract][Full Text] [Related]
9. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918 [TBL] [Abstract][Full Text] [Related]
10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [TBL] [Abstract][Full Text] [Related]
11. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915 [TBL] [Abstract][Full Text] [Related]
14. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920 [TBL] [Abstract][Full Text] [Related]
15. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Abe K; Itoyama Y; Sobue G; Tsuji S; Aoki M; Doyu M; Hamada C; Kondo K; Yoneoka T; Akimoto M; Yoshino H; Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):610-7. PubMed ID: 25286015 [TBL] [Abstract][Full Text] [Related]
16. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Takahashi F; Takei K; Tsuda K; Palumbo J Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Nourelden AZ; Kamal I; Hagrass AI; Tawfik AG; Elhady MM; Fathallah AH; Eshag MME; Zaazouee MS Neurol Sci; 2023 Oct; 44(10):3429-3442. PubMed ID: 37249667 [TBL] [Abstract][Full Text] [Related]
18. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913 [TBL] [Abstract][Full Text] [Related]
19. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411 [TBL] [Abstract][Full Text] [Related]
20. Is edaravone harmful? (A placebo is not a control). Turnbull J Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):477-482. PubMed ID: 30373406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]